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Aims To establish a temporal safety window for cryoablation at minimal temperatures and to assess the electrophysiologi-
cal and histological changes as a function of the application duration.
Methods
and results
Twenty mini-pigs underwent AV nodal cryoablation at 2808C without prior cryomapping. The duration of the
cryoapplication following atrioventricular block (AVB) was randomized to 0, 10, 20, 40, or 60 s. Atrioventricular
block was obtained in all animals after a median of 3 (1–8 interquartile range) applications. One week later, AV
nodal conduction fully recovered in animals with application duration ,10 s, whereas persistent AVB incidence
increased as a function of time in animals with longer applications duration. Cryoablation application duration follow-
ing AVB was the only independent predictor of persistent AVB (OR, 1.116; 95% CI, 1.013–1.229; P ¼ 0.026). There
was no difference in lesion location or size between animals with vs. those without persistent AVB at 1 week.
However, animals randomized to longer application duration demonstrated higher degree of cell destruction and
ﬁbrotic content.
Conclusion In this closed-chest pig model, there was a relation between cryoapplication duration following AVB at 2808C and
recovery of conduction. A safety window of at least 10 s was observed in all cases.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Cryothermal ablation † Atrioventricular block † Perinodal ablation † Atrioventricular node † Supraventricular
tachycardias
Introduction
Cryothermal ablation is increasingly used in high-risk perinodal
ablations, due to the absence of undesired persistent atrioventricu-
lar block (AVB) cases reported in the literature.
1 The ability of this
technology to create reversible lesions at temperatures of 2308C
(cryomapping) is responsible in part for this excellent safety
proﬁle.
1–9 However, the electrophysiological effects may not
always be predicted by prior cryomapping at 2308C and
adverse effects can subsequently be observed during cryoablation
(at 2708 to 2808C).
2–9 In this case, anecdotal reports suggest
that, if the application is immediately interrupted, there is usually
complete recovery of conduction.
2–9 We hypothesized that the
reversibility of cryothermal application at the AV node is depen-
dent, not only on the minimal temperature at the catheter tip,
but also on the duration of the application. Therefore, the
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doi:10.1093/europace/eup310objectives of this study were to: (i) establish a temporal safety
window during AV nodal cryoablation at minimal temperatures
(2808C); (ii) evaluate the residual electrophysiological AV nodal
impairment after reversible lesions at 2808C; and (iii) assess the
histological changes related to the occurrence of AVB as a function
of the duration of the cryoablation application.
Methods
The experimental protocol was approved by the Ethics Committee of
Animal Experimentation of our institution. Twenty mini-pigs of either
sex weighting 30+4 kg were used in this study.
Electrophysiological study
Three quadripolar catheters were positioned using ﬂuoroscopy to the
right atrium, the His bundle, and the right ventricular apex for record-
ing and pacing. Surface electrocardiographic leads and ﬁltered bipolar
intracardiac electrograms were recorded at 100 mm/s paper speed.
Atrial and ventricular stimulation protocols included pacing trains at
a ﬁxed cycle length and the extrastimulus technique.
Atrioventricular conduction properties were assessed at baseline
prior to cryoenergy application, 1 h post-ablation and 1 week later.
The following parameters were recorded: AH and HV intervals, AV
nodal Wenckebach cycle length, AV nodal effective refractory period.
Cryoablation protocol
Percutaneous AV nodal cryoablation was performed using a 9 Fr cath-
eter (Freezor
w Max, CryoCath Technologies Inc., Montreal, Canada).




eter was positioned at the triangle of Koch and cryoenergy at minimal
temperature of 2808C (without prior cryomapping) was delivered at
sites with large low right atrial and small His bundle recordings, aiming
to achieve AVB, deﬁned as the occurrence of two consecutive
P-waves not conducted to the ventricle. Prior to energy delivery, the
duration of the cryoapplication following AVB was randomized to 0,
10, 20, 40, or 60 s (Figure 1). The randomization table was designed to
obtain equally distributed groups (Group 1: 0 s, Group 2: 10 s, Group
3: 20 s, Group 4: 40 s, Group 5: 60 s). The cryoapplication was main-
tained until the temperature reached 2808C and stopped if no AVB
was obtained 30 s after the minimal temperature was reached. In that
case, the catheter was allowed to rewarm and was repositioned to
perform another cryoapplication. Afterwards, a permanent pacemaker
was implanted and animals were kept alive for 1 week. The outcome
variables after cryoablation were: (i) acute AVB: complete AVB 1 h
after the cryoapplication delivery; (ii) acute AV conduction recovery: 1:1
atrial conduction to the ventricle up to 1 h after the cryoapplication
delivery; (iii) delayed AV conduction recovery: AV conduction recovery
that occurred between the end of the procedure up to 1 week later;
and (iv) persistent AVB: complete AVB 1 week after the cryoablation pro-
cedure. The following procedural variables corresponding to the effec-
tive cryoapplication (i.e. causing AVB) were recorded.
– Time to effect: interval from onset of cryoablation application to AVB
occurrence.
– Temperature at AVB: catheter tip temperature at the time of AVB
occurrence.
– Nadir temperature: minimal temperature reached during the
application.
– Time to cryoablation temperature: interval from onset of cryoablation
application to catheter tip temperature  2808C.
– Critical cryoablation application duration: cryoablation application dur-
ation interval from onset of AVB until the end of the application.
Histology
Animals were sacriﬁced at 7 days with a lethal injection of pentobarbi-
tal. Their hearts were explanted, rinsed, and ﬁxed in 10% formalin. At
least four blocks of tissue of the AV junctions were dehydrated and
embedded in parafﬁn. Specimens were serially sectioned perpendicular
to the septal leaﬂet of the tricuspid valve at a thickness of 7–10m m
with a microtome (Microm HM310) and stained with Masson’s
trichrome. Cryolesions size was measured using image analysis
software (SigmaScanPro 5.0, Jandel Scientiﬁc, San Rafael, CA, USA).
The geometry of the cryoablation lesions’ area was calculated as
A ¼ (1/4)p(W/2)D, and the volume was calculated as V ¼ (1/2)(4/3)p
(W/2)
2D,w h e r eW, lesion width and D, lesion depth.
11
Morphometric analysis at light microscopy was restricted to exper-
iments in which AV conduction block was obtained after a single
cryoapplication and to controls. It was performed using digital
images (512   512 pixels) from each tissue block by using a linear
measurement software program (SigmaScan Pro 5.0). Twenty-two
measurements of AV nodal and His myocytes diameter (mm) were
obtained from each tissue block. For each measurement, the widest
cross-sectional myocyte diameter was selected and averaged to
allow comparison with controls. To quantify the amount of
myocyte/connective tissue, morphometry was performed using a
grid of vertical and horizontal lines providing 121 intersections or
points. The total number of intersection points was deﬁned as
100%. The proportion of tissue corresponding to connective tissue
matrix in each specimen was expressed as connective tissue density,
deﬁned as the percentage of intersection points overlying within the
tissue extension limited by the grid. Connective tissue density was esti-
mated in a minimum of eight different randomly chosen ﬁelds of the
AV node and His bundle for each specimen and values were then aver-
aged. Blood vessels and perivascular interstitial tissue were excluded
from connective tissue quantiﬁcation. To quantify the extent of myo-
lysis in the specialized tissue, only myocytes in which the nucleus
was present in the plane of the section were considered and at least
12 myocytes per section were analysed. Myocytes were scored by
morphometry as: (i) normal myocytes, without myolysis, (ii) mildly myo-
lytic if myolysis involved between 15 and 35% of the sarcoplasma, and
(iii) severely myolytic if .40% of the sarcomeres were absent.
In four animals, an electrophysiological study was performed but no
cryoapplications were delivered and they were used as control
specimens.
Statistical analysis
Results are reported for the entire sample (n ¼ 20) unless other-
wise speciﬁed. Continuous variables are reported as mean+SD
or median and interquartile range (IQR), depending on whether
they were normally or non-normally distributed. Categorical vari-
ables are reported as number and percentage. Comparisons were
made using Student’s t-test and the Fisher’s exact test, as appropri-
ate. In case of non-normally distributed continuous variables, Wil-
coxon test was used. Statistically signiﬁcant variables in the
univariate analysis were included in a stepwise logistic regression
model. Analyses were performed with SPSS v14.0 and statistical
signiﬁcance was established at P , 0.05.
Temporal safety window for cryoablation at minimal temperature 1539Results
A total of107 cryoablation applications were delivered at the level of
theAVnode.Atrioventricularblockwasobtainedinallanimalsaftera
median of 3 (1–8 IQR) cryoablation applications. A single application
was needed to obtain AVB in six (30%) animals, two to four in six
(30%), and ﬁve or more applications in the remaining. The mean
minimal temperature recorded during the applications that caused
AVB was 282.3+0.58C. The median temperature at AVB occur-
rence was 2808C( r a n g e250 to 2858C). The mean time to effect
was 31.8+18.7 s and the mean time to cryoablation temperature
 2808C was 22.2+4.1 s. Mean application duration according to
assigned group was: Group 1: 3.75+2.22, Group 2: 14+1.82,
Group 3: 22.5+3.32, Group 4: 41.5+12.37, Group 5: 65+6s .
Atrioventricular conduction acutely recovered in 10 animals
after a median of 55 (range 30–1500) seconds following AVB.
Two additional animals with acute AVB, had delayed AV conduc-
tion recovery 1 week after the ablation procedure. There were
no cases of delayed AVB in the group of animals with acute AV
conduction recovery following cryoablation. Thus, eight animals
had persistent AVB 1 week after the procedure.
Predictors of acute atrioventricular
conduction recovery
Atrioventricular nodal conduction fully recovered in all animals
randomized to cryoablation application duration of 0 and 10 s
following the second-blocked P-wave. No cases of acute AVB
occurred with applications duration lasting  15 s. In univariate
analyses, several variables were associated with the occurrence
of acute conduction recovery, whereas lesion size was not
(Table 1). In multivariate analysis, critical cryoablation application
duration from AVB onset remained as the only signiﬁcant predictor
of acute AV conduction recovery (OR, 0.887; 95% CI, 0.799–
0.984; P ¼ 0.024).
Predictors of persistent atrioventricular
block occurrence
One week after the cryoablation procedure, there were no cases
of persistent AVB in animals randomized to application duration of
0 and 10 s following the second-blocked P-wave, whereas the
probability of presenting persistent AVB increased as a function
of time in animals with longer application duration. Persistent
AVB occurred in one (25%), three (75%), and four (100%)
animals assigned to critical cryoapplication duration of 20, 40,
and 60 s, respectively. The ﬁrst case of persistent AVB occurred
after a 16 s application duration following the second-blocked
P-wave. Several variables were related to the occurrence of per-
sistent AVB in the univariate analyses (Table 1). In a multiple logistic
regression model, critical application duration from AVB onset was
the only independent predictor of persistent AVB (OR, 1.116; 95%
CI, 1.013–1.229; P ¼ 0.026).
Figure 1 Cryoablation protocol. (A) Left: cryoablation application is halted 3 s after AVB occurrence, deﬁned by two consecutive P-waves
not conducted to the ventricle, in an animal randomized to 0 s application duration. (A) Right: acute AV conduction recovery with resumption of
1:1 atrial conduction to the ventricle 30 s after the cryoapplication was interrupted. (B) Left and centre: critical cryoablation application lasting
for 20 s, in an animal randomized to 20 s duration application. (B) Right: acute AVB 1 h after the cryoapplication delivery. In this case, AVB
persisted 1 week after the cryoablation procedure.
F. Atienza et al. 1540Atrioventricular nodal conduction
characteristics following transient
atrioventricular block
A signiﬁcant prolongation of the AH interval was the only electro-
physiological parameter that was affected by the cryoablation
application in animals with AV nodal conduction recovery
(Table 2). Other parameters of AV nodal function fully normalized
at 60 min and at 7 days after cryoablation.
Histology
On qualitative analysis, all cryoablated specimens were consistently
characterized by extensive myocellular damage involving the AV
junction walls. Cryolesions were well-circumscribed discrete
lesions with sharp borders, dense areas of ﬁbrotic tissue, and con-
traction band necrosis (Figure 2). Myocardial tissue displayed
shrunk cells with degenerated cytoplasms, decreased staining,
coagulation necrosis, lymphocytes, and macrophages inﬁltration
(Figure 3). Overall (n ¼ 20), there was no difference in lesion size
between animals with vs. without AVB acutely or 1 week after
the cryoablation procedure (Table 1).
In six animals, AV conduction block was obtained after a
single cryoapplication. Of those, AV nodal conduction acutely
recovered in animals randomized to application duration of 0
and 10 s (n ¼ 2), whereas AVB persisted .1 h after the pro-
cedure in the remaining animals randomized to 20–60 s appli-
cation duration (Table 3). Histologically, all six animals
demonstrated a lesion that affected the proximal AV conduction
system, both the penetrating bundle and a portion of the AV
node. There was no difference in lesion location at the AV
node level or in lesion size between animals with AV nodal con-
duction recovery vs. persistent AVB at 1 week (Figure 2). Mor-
phometric analysis of the cryolesions showed loss of cellular
viability throughout the wall thickness. However, in animals
that subsequently had acute AV conduction recovery (#6, #7),
isolated viable cells surrounded by necrotic tissue were
observed within the lesions of the specialized AV node and
penetrating His bundle (Figure 3). Moreover, the degree of myo-
lytic changes differed between animals with vs. without persist-
ent AVB at 1 week (Table 3 and Figure 3). Animals with AV
conduction recovery showed only mild myolytic changes,
whereas severe myolytic changes (.40% myolytic ﬁbres),
both at the AV node level and the penetrating His bundle,
were observed in animals with persistent AVB (#3, #19, #22).
Similarly, animals with persistent AVB at 1 week demonstrated
higher collagen content when compared with animals with AV
...............................................................................................................................................................................
Table 2 Atrioventricular nodal conduction characteristics before and following cryoablation in animals with
atrioventricular conduction recovery
Baseline Acute (n 5 10) P-value
a 1 Week (n 5 12) P-value
b
AH interval 81.1+8.2 91.1+12.7 0.04 93.6+11.2 0.04
HV interval 32.2+5.6 32.8+6.8 ns 32.3+6.5 ns
Wenckebach cycle 271.1+38.9 268.9+50.8 ns 250.9+43.5 ns
AVN refractory period 600 277.8+32.3 297.8+33.1 ns 283.6+38.3 ns
AVN refractory period 400 245+30.1 223.7+93.5 ns 251+28.1 ns
aBaseline vs. acute.
bBaseline vs. 1 week.
................................................... ....................................
...............................................................................................................................................................................
Table 1 Univariate predictors of acute atrioventricular nodal conduction recovery and persistent atrioventricular block
at 1 week
Acute AV nodal conduction recovery P-value Persistent AVB at 1 week P-value
Yes (n 5 10) No (n 5 10) No (n 5 12) Yes (n 5 8)
Number of applications 6 (11) 3 (3) 0.131 3.5 (10) 3 (6) 0.635
Time to effect 40 (32) 19 (18) 0.016 34.5 (31) 19 (24.3) 0.031
Time to cryoablation temperature 21.55+5.14 23+4.27 0.507 21.83+5.32 22.75+3.88 0.662
Critical cryoablation application duration 13 (18) 49 (42.5) 0.003 14 (17.75) 48 (33.25) 0.010
Temperature at AVB 280 (0) 280 (13) 0.045 280 (0) 278.5 (14) 0.037
Nadir temperature 283 (5) 282 (3.5) 0.614 282.5 (4.5) 282 (4.25) 0.694
Lesion depth 2.95 (0.7) 3 (1.85) 0.682 2.9 (0.5) 3.3 (2.35) 0.281
Lesion area 16.05+7.67 14.7+8.56 0.724 14.94+6.85 16.06+9.63 0.768
Lesion volume 39.45+22.67 40.91+24.63 0.894 40.38+23.15 40+24.56 0.973
Mean+SD; median (interquartile range).
Temporal safety window for cryoablation at minimal temperature 1541conduction recovery and controls. Interestingly, case #17 had
delayed AV conduction recovery at 1 week and showed inter-
mediate myolytic changes and ﬁbrotic content level when com-
pared with animals with acute recovery and persistent AVB.
Finally, a progressive increase in cell size was observed from
controls to persistent AVB animals.
Discussion
The main ﬁndings of the present study are that in this closed-chest
pig model: (i) there is a safety window of at least 10 s during cryoa-
blation at minimal temperatures (2808C), where complete recov-
ery of the AV node electrophysiological properties is always
observed; (ii) the main determinant of the electrophysiological
effects of cryoablation of the AV node at minimal temperatures
is application duration, but not lesion size; (iii) changes at the
microscopic level, such as cell destruction and ﬁbrosis, explain
the irreversible electrophysiological effects demonstrated by appli-
cations duration lasting .15 s.
Undesired atrioventricular block during
cryoablation at 2808 8 8 8 8C
As opposed to radiofrequency ablation, there are no cases
reported in the literature of undesired persistent AVB during
cryoablation.
1–9 For this reason, cryoablation has become a very
attractive alternative to radiofrequency during perinodal ablations,
particularly in young individuals in whom AVB would be a disas-
trous outcome. In this setting, cryomapping at 2308C creates
reversible lesions that enable testing the functional effects of abla-
tion before the formation of a permanent lesion.
1,2,10 However,
the electrophysiological effects may not always be predicted by
prior cryomapping at 2308C and adverse effects can be observed
during cryoablation (at 270 to 2808C).
2–9 We and others have
reported the occurrence of transient high-grade AVB during cryoa-
blation at sites where previous cryomapping was judged to be ‘safe’
as veriﬁed using a navigation system.
2,7 Although gradual normali-
zation of the electrophysiological properties has been observed
when the application is immediately interrupted, no information
exists to date regarding the safety proﬁle of cryoablation in this
situation.
Application duration as a determinant
of the electrophysiological effect
Permanence of tissue destruction with cryothermal energy is
related to time-dependent variables and tissue tempera-
ture.
1,9,12–15 Holman et al.
16 ﬁrst reported the occurrence of
undesired AVB during selective cryosurgical ablation (2608C) of
the perinodal tissue that completely resolved over time if the
cryothermic exposure was immediately terminated. They also
found that despite prolongation of AH and VA intervals, Wencke-
bach point, and AV nodal effective refractory period in the immedi-
ate post-operative period, all these variables normalized by 14 days
after surgery except for the AH interval. In our study, only a signiﬁ-
cant prolongation in the AH interval following transient AVB at
2808C was observed acutely and 1 week later. Also in agreement
with them, no instances of persistent AVB were observed during
follow-up in our study after applications lasting ,16 s.
Several clinical studies in humans have reported the occurrence
of undesired transient AVB during cryoablation applications at
temperatures  2708C.
2–9 In all cases AVB resolved completely,
usually within a few seconds or minutes, with PR interval and
Wenckebach point returning to baseline. In those studies, no
patient had persistent AVB or required pacemaker implantation.
The present study conﬁrms the benign outcome of undesired
complete AVB that occurs during cryoablation at 2808C. More-
over, the observation that there were two cases of delayed AV
conduction recovery and no cases of AV nodal conduction impair-
ment 1 week following cryoablation suggests that long-term
deterioration is unlikely. However, although either acute or
delayed AV nodal conduction recovery can be observed with appli-
cations lasting .15 s, the probability of persistent AVB occurrence
signiﬁcantly increased over that application duration, indicating
Figure 2 Cryolesions histological characteristics at the AV
node level. Control experiment (A) and cryolesion histological
characteristics at the AV node level in three specimens (B–D)
1 week after a single cryoenergy application that produced AVB
(dotted blue line ¼ AV node), when stained with Masson’s tri-
chrome. Note shape of the lesion resembling a prolate hemi-
sphere (dotted yellow line) and the homogeneous nature of
cryolesion, with a smooth and sharp demarcation from intact
myocardium, with replacement of muscle by granulation tissue
at perimeter of the lesion and coagulative necrosis of underlying
myocardium. TV, tricuspid valve; CFB, central ﬁbrous body; VS,
ventricular septum.
F. Atienza et al. 1542that, in fact, permanent AV nodal block occurs with long enough
cryoenergy applications.
Other authors have failed to obtain persistent AVB in a signiﬁ-
cant proportion of patients with clinical indication of AV node abla-
tion, despite delivering long duration cryoenergy applications
preceded by multiple cryomapping attempts.
4,14 Several circum-
stances may explain their results, such as smaller catheter tip
size (4–6 mm), catheter tip–heart size mismatch, tissue oedema
as a consequence of multiple consecutive cryomapping and cryoa-
blation attempts, and higher temperatures during cryoablation.
4,14
Our results conﬁrm the ability of long enough cryoablation appli-
cations (.60 s) to consistently produce persistent AVB when large
catheters (8 mm) are used and very low temperatures (,2808C)
are reached.
Characteristics of the cryolesion
Several hypotheses have been proposed to explain the reversibility
of the electrophysiological effects during cryoablation such as
iceball enlargement and temperature gradient effect on tissues in
the proximity of the catheter tip, but none has systematically ana-
lysed the histological correlates of reversibility of the electro-
physiological effects.
8,9 In the present in vivo study using
cryoablation at minimal temperatures (2808C), we found no
differences in lesion location or in lesion size between animals
with vs. those without persistent AVB, application duration being
the only independent predictor of AV nodal conduction recovery.
Separate analysis of experiments in which AVB was obtained with a
single application conﬁrmed these results.
At minimal temperatures, cryothermal energy created a well-
deﬁned lesion with sharp borders displaying the characteristic fea-
tures previously described (Figure 2).
11–13,16,17 We performed
morphometric analysis of the lesions to get further insights into
the factors determining normalization of the electrophysiological
conduction properties. The degree of myolytic changes and col-
lagen content of the lesion increased as a function of the critical
cryoapplication duration, thereby determining the electrophysio-
logical effect. Interestingly, strands of isolated viable cells sur-
rounded by necrotic tissue were observed within the lesions of
the specialized conduction system in animals that subsequently
showed AV conduction recovery (Figure 3). Similar ﬁndings were
observed by Fujino et al.
17 in animals demonstrating late AV con-
duction recovery at 6 weeks following percutaneous AVB cryoa-
blation attempts. Thus, applications lasting ,15 s from the
electrophysiological effect onset create a well-deﬁned lesion, but
enable some viable cells to survive. However, the long-term
outcome of these lesions remains unknown and studies are
needed to establish the risk of delayed (.1 week) AVB develop-
ment under these conditions.
Figure 3 AV nodal myocytes characteristics after a single cryoenergy application in relation to AVB occurrence at 1 week (corresponds to
Figure 2 magniﬁcation at the AV node level). AV nodal myocytes in control specimen (A) and after a single cryoenergy application in relation to
AVB occurrence at 1 week (B–D). (A) Control specimen, showing normal AV nodal cells. (B) Isolated viable cells (arrows) surrounded by necro-
tic cells in animal #6 (acute AV recovery). (C) Moderate degenerative changes characterized by loss of contractile material (arrows) and mild
collagen inﬁltration in animal #17 (delayed AV conduction recovery at 1 week). (D) Severe myolytic changes and dense collagenous scar with
coagulative necrosis in animal #22 (persistent AVB).
Temporal safety window for cryoablation at minimal temperature 1543Limitations
Several limitations in our work should be discussed. First, lesion
size can depend on several conditions such as electrode orien-
tation, contact pressure, and blood velocity that were not con-
trolled for in the present study.
12,13 For this reason, application
duration was randomly assigned to partially overcome this limit-
ation. Second, more than one cryoablation application was
needed to obtain AVB in two-thirds of the experiments. To
avoid bias caused by the possibility of lesion conﬂuence and the
effect of consecutive freeze–thaw cycles, morphometric analysis
was limited to experiments in which AVB was obtained with a
single application. Nevertheless, ineffective applications are most
likely due to inadequate position not affecting the AV node
17
and, in most cases, consecutive cryolesions could be individualized
in our study. Finally, longer term observations in humans are
needed to conﬁrm the favourable outcome of reversible lesions
created at minimal temperatures in this model.
Clinical implications
More aggressive strategies are used with the aim of increasing
success rates and reducing recurrences during cryoablation. In
patients with atrioventricular nodal reentrant tachycardia, larger
tip cryoablation catheters are associated with fewer recurrences
in long-term follow-up.
8 Similarly, in patients undergoing AV
nodal therapeutic ablation, long lasting applications using large
catheters (i.e. 8 mm) and catheter tip temperatures  2808C
should be needed to consistently obtain persistent AVB. In patients
with accessory pathways, it has been suggested that substituting
cryomapping by direct cryoablation controlling ‘time to success’
can achieve a high success rate.
9 Our study suggests that, even
using low temperatures (2808C) and large tip electrodes, no
persistent AVB could be expected during perinodal cryoablation
if the application duration is halted within 10 s of AVB onset.
These results might be useful in further deﬁning the role of
this energy for ablation of arrhythmic substrates at high risk
of AVB.
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